- Home
- SHO vs DNLI Comparison
SHO vs DNLI Comparison
Compare SHO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHO
- DNLI
- Stock Information
- Founded
- SHO 1995
- DNLI 2013
- Country
- SHO United States
- DNLI United States
- Employees
- SHO N/A
- DNLI N/A
- Industry
- SHO Hotels/Resorts
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHO Consumer Discretionary
- DNLI Health Care
- Exchange
- SHO Nasdaq
- DNLI Nasdaq
- Market Cap
- SHO 1.8B
- DNLI 2.1B
- IPO Year
- SHO 1995
- DNLI 2017
- Fundamental
- Price
- SHO $9.92
- DNLI $13.18
- Analyst Decision
- SHO Hold
- DNLI Strong Buy
- Analyst Count
- SHO 7
- DNLI 16
- Target Price
- SHO $9.21
- DNLI $33.62
- AVG Volume (30 Days)
- SHO 2.2M
- DNLI 2.1M
- Earning Date
- SHO 11-11-2025
- DNLI 11-05-2025
- Dividend Yield
- SHO 3.70%
- DNLI N/A
- EPS Growth
- SHO N/A
- DNLI N/A
- EPS
- SHO 0.02
- DNLI N/A
- Revenue
- SHO $934,999,000.00
- DNLI N/A
- Revenue This Year
- SHO $6.47
- DNLI N/A
- Revenue Next Year
- SHO $3.90
- DNLI $95,463.19
- P/E Ratio
- SHO $452.22
- DNLI N/A
- Revenue Growth
- SHO 0.37
- DNLI N/A
- 52 Week Low
- SHO $7.45
- DNLI $10.57
- 52 Week High
- SHO $12.41
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- SHO 65.08
- DNLI 35.41
- Support Level
- SHO $9.50
- DNLI $13.04
- Resistance Level
- SHO $10.27
- DNLI $13.86
- Average True Range (ATR)
- SHO 0.24
- DNLI 0.75
- MACD
- SHO 0.03
- DNLI -0.29
- Stochastic Oscillator
- SHO 66.02
- DNLI 4.43
About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.